World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
78
Citations
27921
World Ranking
1729
National Ranking
850

Mark J. Mulligan publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Mark J. Mulligan sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 239 publications — 48th percentile

48% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Mark J. Mulligan D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Mark J. Mulligan sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 78 D-Index — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Mark J. Mulligan is affiliated with New York University in the United States. Their research primarily focuses on Medicine, with a strong emphasis on Infectious Diseases, Immunology, and Epidemiology. This work also touches on related fields such as Molecular Biology and Animal Science and Zoology.

The scientist's research extensively covers topics connected to SARS-CoV-2 and COVID-19, including clinical research studies, detection and testing methods, vaccine coverage and hesitancy, as well as immunotherapy and immune responses. Additionally, their work includes investigations into animal virus infections and influenza virus research.

Recent notable publications by Mark J. Mulligan include:

  • Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults, 2020, Nature
  • Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates, 2020, New England Journal of Medicine
  • Homologous and Heterologous Covid-19 Booster Vaccinations, 2022, New England Journal of Medicine
  • The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates, 2021, Science Translational Medicine
  • Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials, 2021, Nature Communications

Mark J. Mulligan frequently collaborates with fellow researchers such as Marie I. Samanovic, Nadine Rouphael, Ramin S. Herati, Evan J. Anderson, and Lilin Lai.

The scientist's work has appeared in several publication venues, with multiple contributions to bioRxiv (Cold Spring Harbor Laboratory), Vaccines, Vaccine, Open Forum Infectious Diseases, and The Journal of Infectious Diseases.

Best Publications

  • Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.

    Edward E. Walsh;Robert W. Frenck;Ann R. Falsey;Ann R. Falsey;Nicholas Kitchin

  • Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.

    Mark J. Mulligan;Kirsten E. Lyke;Nicholas Kitchin;Judith Absalon

  • Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

    Troy D Querec;Rama Akondy;Eva K Lee;Weiping Cao

  • Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

    Jens Wrammert;Dimitrios G. Koutsonanos;Gui-Mei Li;Srilatha Edupuganti

  • Homologous and Heterologous Covid-19 Booster Vaccinations

    Unknown

  • Molecular signatures of antibody responses derived from a systems biology study of five human vaccines

    Shuzhao Li;Nadine Rouphael;Sai Duraisingham;Sandra Romero-Steiner

  • Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine

    Scott M. Hammer;Magdalena E. Sobieszczyk;Holly Janes;Shelly T. Karuna

  • Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines.

    Joseph D. Miller;Robbert G. van der Most;Rama S. Akondy;John T. Glidewell

  • Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus

    Lalita Priyamvada;Kendra M. Quicke;William H. Hudson;Nattawat Onlamoon

  • Origin and differentiation of human memory CD8 T cells after vaccination

    Rama Akondy;Mark Fitch;Srilatha Edupuganti;Shu Yang

  • The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial

    Nadine G Rouphael;Michele Paine;Regina Mosley;Sebastien Henry

  • Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells

    Gui-Mei Li;Christopher Chiu;Jens Wrammert;Megan McCausland

  • Magnitude of Functional CD8+ T-Cell Responses to the Gag Protein of Human Immunodeficiency Virus Type 1 Correlates Inversely with Viral Load in Plasma

    Bradley H. Edwards;Anju Bansal;Steffanie Sabbaj;Janna Bakari

  • The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.

    Bryan E. Jones;Patricia L. Brown-Augsburger;Kizzmekia S. Corbett;Kathryn Westendorf

  • Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

    Unknown

  • The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8+ T Cell Response

    Rama S. Akondy;Nathan D. Monson;Joseph D. Miller;Srilatha Edupuganti

  • Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.

    Ann R Falsey;Magdalena E Sobieszczyk;Ian Hirsch;Stephanie Sproule

  • Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared Molecular Signatures

    Helder I. Nakaya;Thomas Hagan;Sai S. Duraisingham;Eva K. Lee

  • Protection against vaginal SIV transmission with microencapsulated vaccine

    Preston A. Marx;Richard W. Compans;Agegnehu Gettie;Jay K. Staas

  • Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

    Martin R Gaudinski;Katherine V Houser;Kaitlyn M Morabito;Zonghui Hu

  • Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.

    Cathrine Axfors;Cathrine Axfors;Andreas M. Schmitt;Andreas M. Schmitt;Perrine Janiaud;Janneke van’t Hooft;Janneke van’t Hooft

  • A Canarypox Vaccine Expressing Multiple Human Immunodeficiency Virus Type 1 Genes Given Alone or with Rgp120 Elicits Broad and Durable CD8+ Cytotoxic T Lymphocyte Responses in Seronegative Volunteers

    Thomas G. Evans;Michael C. Keefer;Kent J. Weinhold;Mark Wolff

Frequent Co-Authors

Nadine Rouphael
Nadine Rouphael Emory University
Rafi Ahmed
Rafi Ahmed Emory University
Paul A. Goepfert
Paul A. Goepfert University of Alabama at Birmingham
M. Juliana McElrath
M. Juliana McElrath University of Washington
Sharon E. Frey
Sharon E. Frey Saint Louis University
Bali Pulendran
Bali Pulendran Stanford University
Michael C. Keefer
Michael C. Keefer University of Rochester
Barney S. Graham
Barney S. Graham Morehouse School of Medicine
Robert B. Belshe
Robert B. Belshe Saint Louis University
Wendy A. Keitel
Wendy A. Keitel Baylor College of Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related fields such as nursing can open diverse career opportunities. Many professionals consider advanced nursing roles specializing in mental health and psychiatric care, which often require strong clinical skills and advanced degrees.

One can pursue an easiest np program to start building foundational knowledge before moving into specialized areas like psychiatric mental health nurse practitioner roles. These programs balance accessibility with quality education, making them a popular choice for busy students.

When looking for specialized training, online options for online pmhnp programs with clinical placement are invaluable. They provide hands-on clinical experience, essential for certification and real-world practice, even in a virtual learning environment.

Cost is another critical factor; finding the cheapest psych np programs online can make advanced education more accessible without sacrificing quality. Scholarships and flexible payment plans often accompany these affordable programs.

Finally, understanding the financial outlook is important. According to recent data on doctorate in nursing salary, earning potential varies by location but generally reflects rewarding compensation for advanced practitioners.

Best Scientists Citing Mark J. Mulligan

Trending Scientists

Recently Published Articles